Reviewing Fobi AI (OTCMKTS:FOBIF) and MDxHealth (NASDAQ:MDXH)

Fobi AI (OTCMKTS:FOBIF) and MDxHealth (NASDAQ:MDXH) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Fobi AI and MDxHealth, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fobi AI	0	0	0	0	N/A
MDxHealth	0	0	4	0	3.00

MDxHealth has a consensus price target of $28.33, suggesting a potential upside of 937.85%. Given MDxHealth’s higher probable upside, analysts plainly believe MDxHealth is more favorable than Fobi AI.

Profitability

This table compares Fobi AI and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fobi AI	-321.37%	-277.82%	-161.05%
MDxHealth	N/A	N/A	N/A

Earnings & Valuation

This table compares Fobi AI and MDxHealth’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fobi AI	$1.51 million	8.03	-$9.44 million	($0.04)	-1.38
MDxHealth	$75.33 million	0.06	-$43.10 million	N/A	N/A

Fobi AI has higher earnings, but lower revenue than MDxHealth.

Risk and Volatility

Fobi AI has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Summary

MDxHealth beats Fobi AI on 7 of the 9 factors compared between the two stocks.

About Fobi AI

Fobi AI Inc., together with its subsidiaries, operates as a technology and data intelligence company in North America and Europe. It provides software as a service; consulting and development services; and resells, refers, and licenses its products. The company also offers mobile wallet solutions, digital coupons, and customer insights solutions. It serves various industries, including the hospitality and tourism industries. The company was formerly known as Loop Insights Inc. Fobi AI Inc. is based in Vancouver, Canada.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.